Dr Adrian Hill is the Head of HealthTec Development for Harwell Campus, focused on enhancing the health and life sciences ecosystem through strategic business support, networking and partnership. Building on the existing community of Medtech, Diagnostics and Pharmaceutical industry, UK public bodies (STFC, MRC and PHE), academia and core imaging and data capabilities offered by the National Facilities, as well as recent Government investments including the Rosalind Franklin Institute and Vaccine Manufacturing and Innovation Centre, Adrian actively supports internal and external members of the HealthTec Cluster to ensure Harwell is well positioned for growth in targeted business sectors, to strengthen the local economy.
Prior to joining the STFC Adrian obtained a PhD in developmental toxicology at the University of Liverpool, postdoctoral training at the Institut de Génétique et de Biologie Moléculaire et Cellulaire in Strasbourg and the University of Wisconsin-Madison, USA and subsequent qualifications in Business Administration. For many years he was actively involved in the toxicology and preclinical drug discovery conference circuit and published a number of associated research articles and book chapters. He joined VASTox plc as a principal scientist in 2005 tasked with developing new models for screening drug toxicity, safety and efficacy, and in 2006 became Head of Toxicology at Summit plc, an SME drug discovery company focused primarily on musculoskeletal disorders. From 2009 Adrian led ADMET teams in the UK and Singapore as Associate Director at Evotec AG and was also a Business Development Manager tasked with selling niche services to the pharmaceutical and agrochemical community over a global territory. From 2012 he transferred back to the public sector working for two Russell Group universities – the University of Nottingham as a Senior Executive in Corporate Partnerships and subsequently the University of Exeter, as Senior Manager Impact and Partnerships Development. Both roles were at the interface between industry, academia, NHS and Government, tasked with advancing research towards the clinic, supporting entrepreneurs and building innovative collaborations. In 2014 he also became a Board Director for Exonate, a SME spin-out focused on ophthalmic and oncology-related drug discovery. Collectively Adrian brings a wealth of cross-sector knowledge and partnering expertise to the cluster.